MedTrace Logo

Human Sperm Markers of Cryodamage Resistance

NCT02535377 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2021-02-10

No results posted yet for this study

Summary

Sperm freezing has been employed for decades for male fertility preservation in cases of foreseeable or unexpected loss of fertility to guarantee future paternity, and also as a complement of assisted reproduction techniques.

Sperm quality after thawing is highly variable, even among consecutive samples from the same individual, with mean survival rates around 40%. To date, the molecular basis of the adequate resistance or intolerance to freezing/thawing protocols is unknown, and its knowledge can lead to improvement in the selection of the samples to be frozen and also in the adequate supplement of cryopreservation media. Microarray analysis provides a powerful tool to address the molecular explanation beyond this behaviour, yielding results about comparative messenger ribonucleic acid (mRNA)expression under the two different biological conditions: optimal and suboptimal survival.

Then, the aim of the investigators' study is to determine the genomic profile of sperm samples depending on their survival resistance to cryopreservation, to determine genes involved in cryodamage sensitivity.

Conditions

Interventions

OTHER

Sperm cryopreservation

Sperm from the different groups are cryopreserved to evaluate their resistance to preservation.

Sponsors & Collaborators

  • Igenomix

    collaborator INDUSTRY

  • Instituto Valenciano de Infertilidad, IVI Alicante

    lead OTHER

Principal Investigators

  • Elena Sellés, PhD · Instituto Valenciano de Infertilidad, IVI Alicante

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-12
Primary Completion
2018-11-12
Completion
2019-12-12

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02535377 on ClinicalTrials.gov